Cargando…
Genome editing of oncogenes with ZFNs and TALENs: caveats in nuclease design
BACKGROUND: Gene knockout technologies involving programmable nucleases have been used to create knockouts in several applications. Gene editing using Zinc-finger nucleases (ZFNs), Transcription activator like effectors (TALEs) and CRISPR/Cas systems has been used to create changes in the genome in...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198504/ https://www.ncbi.nlm.nih.gov/pubmed/30386178 http://dx.doi.org/10.1186/s12935-018-0666-0 |
_version_ | 1783364978047188992 |
---|---|
author | Shankar, Sumitra Sreekumar, Ahalya Prasad, Deepti Das, Ani V. Pillai, M. Radhakrishna |
author_facet | Shankar, Sumitra Sreekumar, Ahalya Prasad, Deepti Das, Ani V. Pillai, M. Radhakrishna |
author_sort | Shankar, Sumitra |
collection | PubMed |
description | BACKGROUND: Gene knockout technologies involving programmable nucleases have been used to create knockouts in several applications. Gene editing using Zinc-finger nucleases (ZFNs), Transcription activator like effectors (TALEs) and CRISPR/Cas systems has been used to create changes in the genome in order to make it non-functional. In the present study, we have looked into the possibility of using six fingered CompoZr ZFN pair to target the E6 gene of HPV 16 genome. METHODS: HPV 16(+ve) cell lines; SiHa and CaSki were used for experiments. CompoZr ZFNs targeting E6 gene were designed and constructed by Sigma-Aldrich. TALENs targeting E6 and E7 genes were made using TALEN assembly kit. Gene editing was monitored by T7E1 mismatch nuclease and Nuclease resistance assays. Levels of E6 and E7 were further analyzed by RT-PCR, western blot as well as immunoflourescence analyses. To check if there is any interference due to methylation, cell lines were treated with sodium butyrate, and Nocodazole. RESULTS: Although ZFN editing activity in yeast based MEL-I assay was high, it yielded very low activity in tumor cell lines; only 6% editing in CaSki and negligible activity in SiHa cell lines. Though editing efficiency was better in CaSki, no significant reduction in E6 protein levels was observed in immunocytochemical analysis. Further, in silico analysis of DNA binding prediction revealed that some of the ZFN modules bound to sequence that did not match the target sequence. Hence, alternate ZFN pairs for E6 and E7 were not synthesized since no further active sites could be identified by in silico analyses. Then we designed TALENs to target E6 and E7 gene. TALENs designed to target E7 gene led to reduction of E7 levels in CaSki and SiHa cervical cancer cell lines. However, TALEN designed to target E6 gene did not yield any editing activity. CONCLUSIONS: Our study highlights that designed nucleases intended to obtain bulk effect should have a reasonable editing activity which reflects phenotypically as well. Nucleases with low editing efficiency, intended for generation of knockout cell lines nucleases could be obtained by single cell cloning. This could serve as a criterion for designing ZFNs and TALENs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12935-018-0666-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6198504 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-61985042018-10-31 Genome editing of oncogenes with ZFNs and TALENs: caveats in nuclease design Shankar, Sumitra Sreekumar, Ahalya Prasad, Deepti Das, Ani V. Pillai, M. Radhakrishna Cancer Cell Int Primary Research BACKGROUND: Gene knockout technologies involving programmable nucleases have been used to create knockouts in several applications. Gene editing using Zinc-finger nucleases (ZFNs), Transcription activator like effectors (TALEs) and CRISPR/Cas systems has been used to create changes in the genome in order to make it non-functional. In the present study, we have looked into the possibility of using six fingered CompoZr ZFN pair to target the E6 gene of HPV 16 genome. METHODS: HPV 16(+ve) cell lines; SiHa and CaSki were used for experiments. CompoZr ZFNs targeting E6 gene were designed and constructed by Sigma-Aldrich. TALENs targeting E6 and E7 genes were made using TALEN assembly kit. Gene editing was monitored by T7E1 mismatch nuclease and Nuclease resistance assays. Levels of E6 and E7 were further analyzed by RT-PCR, western blot as well as immunoflourescence analyses. To check if there is any interference due to methylation, cell lines were treated with sodium butyrate, and Nocodazole. RESULTS: Although ZFN editing activity in yeast based MEL-I assay was high, it yielded very low activity in tumor cell lines; only 6% editing in CaSki and negligible activity in SiHa cell lines. Though editing efficiency was better in CaSki, no significant reduction in E6 protein levels was observed in immunocytochemical analysis. Further, in silico analysis of DNA binding prediction revealed that some of the ZFN modules bound to sequence that did not match the target sequence. Hence, alternate ZFN pairs for E6 and E7 were not synthesized since no further active sites could be identified by in silico analyses. Then we designed TALENs to target E6 and E7 gene. TALENs designed to target E7 gene led to reduction of E7 levels in CaSki and SiHa cervical cancer cell lines. However, TALEN designed to target E6 gene did not yield any editing activity. CONCLUSIONS: Our study highlights that designed nucleases intended to obtain bulk effect should have a reasonable editing activity which reflects phenotypically as well. Nucleases with low editing efficiency, intended for generation of knockout cell lines nucleases could be obtained by single cell cloning. This could serve as a criterion for designing ZFNs and TALENs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12935-018-0666-0) contains supplementary material, which is available to authorized users. BioMed Central 2018-10-22 /pmc/articles/PMC6198504/ /pubmed/30386178 http://dx.doi.org/10.1186/s12935-018-0666-0 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Primary Research Shankar, Sumitra Sreekumar, Ahalya Prasad, Deepti Das, Ani V. Pillai, M. Radhakrishna Genome editing of oncogenes with ZFNs and TALENs: caveats in nuclease design |
title | Genome editing of oncogenes with ZFNs and TALENs: caveats in nuclease design |
title_full | Genome editing of oncogenes with ZFNs and TALENs: caveats in nuclease design |
title_fullStr | Genome editing of oncogenes with ZFNs and TALENs: caveats in nuclease design |
title_full_unstemmed | Genome editing of oncogenes with ZFNs and TALENs: caveats in nuclease design |
title_short | Genome editing of oncogenes with ZFNs and TALENs: caveats in nuclease design |
title_sort | genome editing of oncogenes with zfns and talens: caveats in nuclease design |
topic | Primary Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198504/ https://www.ncbi.nlm.nih.gov/pubmed/30386178 http://dx.doi.org/10.1186/s12935-018-0666-0 |
work_keys_str_mv | AT shankarsumitra genomeeditingofoncogeneswithzfnsandtalenscaveatsinnucleasedesign AT sreekumarahalya genomeeditingofoncogeneswithzfnsandtalenscaveatsinnucleasedesign AT prasaddeepti genomeeditingofoncogeneswithzfnsandtalenscaveatsinnucleasedesign AT dasaniv genomeeditingofoncogeneswithzfnsandtalenscaveatsinnucleasedesign AT pillaimradhakrishna genomeeditingofoncogeneswithzfnsandtalenscaveatsinnucleasedesign |